Impact BioMedical financials
$5.61−1.41%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0K | $7.0K | $7.0K | $18.0K | $7.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | -$16.0K | $7.0K | -$415.0K | $17.0K | -$12.0K | $0.00 | $0.00 | $0.00 |
| Gross margin | −533.3% | 100.0% | −5928.6% | 94.4% | −171.4% | — | — | — |
| Operating income | -$702.0K | -$2.3M | -$1.2M | -$948.0K | -$1.2M | -$1.0M | -$26.2M | -$1.1M |
| Net income | -$699.0K | -$2.3M | $5.2M | -$1.5M | -$14.3M | -$1.3M | -$27.1M | $4.2M |
| Net margin | −23300.0% | −32671.4% | 74928.6% | −8166.7% | −204942.9% | — | — | — |
| Diluted EPS | $-0.13 | $-0.25 | $0.74 | $-1.51 | $-14.89 | $-1.39 | — | $0.76 |
| EBITDA | -$418.0K | -$2.0M | -$872.0K | -$660.0K | -$865.0K | -$727.0K | -$596.0K | -$846.0K |
| Operating cash flow | $470.0K | -$464.0K | $99.0K | -$613.0K | -$694.0K | -$682.0K | -$986.0K | -$1.0M |
| Free cash flow | $470.0K | -$464.0K | $99.0K | -$613.0K | -$694.0K | -$682.0K | -$986.0K | -$1.0M |
| Diluted shares | 8.5M | 8.5M | 7.1M | 1.0M | 1.0M | 1.0M | — | 5.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.0K | $20.0K | $3.0K | $12.0K | $624.0K | $1.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $22.9M | $22.4M | $9.1M |
| Total assets | $16.7M | $17.1M | $17.4M | $18.2M | $19.1M | $20.1M |
| Total liabilities | $2.7M | $2.4M | $1.9M | $27.1M | $26.4M | $13.2M |
| Shareholders' equity | $14.0M | $14.7M | $15.6M | -$8.9M | -$7.4M | $6.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology